AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15327915 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload consumed 20 min before test meal
Number of subjects: 32
Study 15327915 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload consumed 2 h before test meal
Number of subjects: 32
Study 10938022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.0 g eicosapentaenoic acid/docosahexaenoic acid per day)
Number of subjects: 55
Study 10938022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 55
Study 9262809 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 9262809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step method
Number of subjects: 10
Study 7965682 — intervention group
Group type: COMPARATOR
Intervention: One-step method
Number of subjects: 10
Study 7965682 — intervention group
Group type: COMPARATOR
Intervention: Midgait method
Number of subjects: 10
Study 3313686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.3 mg/kg intravenously)
Number of subjects: 10
Study 3313686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 10
Study 3313686 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (placebo)
Number of subjects: 10
Study 30038151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valproic acid (VPA) 500 mg once a day for 3 months
Number of subjects: 31
Study 30038151 — intervention group
Group type: COMPARATOR
Intervention: Control group continued on glaucoma therapy (n = 33 eyes)
Number of subjects: 31
Study 26945271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (Detrol LA) extended release daily for 12 weeks
Number of subjects: 58
Study 26945271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal estradiol cream (Estrace) nightly for 6 weeks then twice per week for 12 weeks
Number of subjects: 58
Study 26945271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (intravaginal estradiol + tolterodine) at 24 weeks
Number of subjects: 58
Study 26945271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (intravaginal estradiol + tolterodine) at 52 weeks
Number of subjects: 58
Study 26945271 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine group
Number of subjects: 58
Study 26945271 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal estradiol group
Number of subjects: 58
Study 25010223 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization
Number of subjects: 0
Study 25010223 — intervention group
Group type: COMPARATOR
Intervention: Surveillance and isolation procedures with or without targeted decolonization
Number of subjects: 0
Study 22918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of zolmitriptan 5 mg orodispersible tablet
Number of subjects: 26
Study 22918855 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of zolmitriptan 5 mg orodispersible tablet
Number of subjects: 26
Study 20360244 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load measurements using semiquantitative real-time RT-PCR for norovirus diagnosis
Number of subjects: 2000000
Study 18487744 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based scoring tool (tablet PC with standalone scoring application for TISS, SAPS2, and Apache 2)
Number of subjects: 0
Study 18487744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the traditional scoring method)
Number of subjects: 0
Study 15787917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 50
Study 15787917 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg x kg(‐1) orally, 30 min before surgery)
Number of subjects: 50
Study 15787917 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study 12853806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises (PMEs)
Number of subjects: 139
Study 12853806 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) for 15 minutes twice daily
Number of subjects: 139
Study 12853806 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BFB) for 15 minutes twice daily
Number of subjects: 139
Study 12853806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 139
Study 10391261 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR surgery and medication
Number of subjects: 86
Study 10391261 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 86
Study 8937258 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized preventive intervention trials
Number of subjects: 0
Study 8937258 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of successful interventions
Number of subjects: 0
Study 1323943 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg orally five times per day for 7 days
Number of subjects: 148
Study 1323943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 6859248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sincere group (S)
Number of subjects: 36
Study 6859248 — intervention group
Group type: COMPARATOR
Intervention: Faker group (F)
Number of subjects: 36
Study 31830963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with heat stress
Number of subjects: 30
Study 31830963 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-intensity resistance training alone)
Number of subjects: 30
Study 29957401 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) adjuvant therapy to the long down regulation protocol
Number of subjects: 240
Study 29957401 — intervention group
Group type: COMPARATOR
Intervention: Control group (long protocol alone)
Number of subjects: 240
Study 26756806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood staining before brilliant blue (BB) staining
Number of subjects: 60
Study 26756806 — intervention group
Group type: COMPARATOR
Intervention: Conventional brilliant blue (BB) staining
Number of subjects: 60
Study 25191933 — intervention group
Group type: EXPERIMENTAL
Intervention: Periacetabular osteotomy (PAO)
Number of subjects: 23
Study 25191933 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 23026181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid (mometasone furoate nasal spray)
Number of subjects: 48
Study 23026181 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine (fexofenadine)
Number of subjects: 48
Study 19786416 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-Supplementing Kidney Yang (WSKY) added to risperidone
Number of subjects: 120
Study 19786416 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to risperidone
Number of subjects: 120
Study 17463412 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily)
Number of subjects: 1513
Study 17463412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (Ovcon 35, 35 microg ethinyl estradiol, and 0.4 mg norethindrone)
Number of subjects: 78
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF-I (30 microg/kg sc twice a day)
Number of subjects: 78
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Estrogen and rhIGF-I
Number of subjects: 78
Study 15292338 — intervention group
Group type: COMPARATOR
Intervention: Control (rhIGF-I placebo and no E)
Number of subjects: 78
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I alone
Number of subjects: 78
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIGF-I and E
Number of subjects: 78
Study 15292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 78
Study 11853331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 days
Number of subjects: 69
Study 11853331 — intervention group
Group type: COMPARATOR
Intervention: Bovine colostrum (BC)
Number of subjects: 69
Study 11853331 — intervention group
Group type: EXPERIMENTAL
Intervention: HBC and BC with pivmecillinam 50 mg kg(‐1) d(‐1) for 5 days
Number of subjects: 69
Study 11477880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 26
Study 11477880 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 26
Study 7868973 — intervention group
Group type: COMPARATOR
Intervention: LDL-apheresis without statin therapy
Number of subjects: 14
Study 7868973 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis with statin therapy (lovastatin or pravastatin)
Number of subjects: 14
Study 3364227 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Behavioral Marital Therapy (BMT)
Number of subjects: 36
Study 3364227 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional Marital Therapy
Number of subjects: 36
Study 3364227 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 28899735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus ephedrine (7.5-15mg)
Number of subjects: 133
Study 28899735 — intervention group
Group type: COMPARATOR
Intervention: Bolus phenylephrine (50-100µg)
Number of subjects: 133
Study 26686571 — intervention group
Group type: EXPERIMENTAL
Intervention: $5-off Tdap voucher
Number of subjects: 95
Study 26686571 — intervention group
Group type: EXPERIMENTAL
Intervention: Free voucher
Number of subjects: 95
Study 26686571 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a 1min video PSA about Tdap vaccination
Number of subjects: 95
Study 26686571 — intervention group
Group type: EXPERIMENTAL
Intervention: No PSA
Number of subjects: 95
Study 26686571 — intervention group
Group type: COMPARATOR
Intervention: Retail pharmacy vouchers
Number of subjects: 95
Study 24815298 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove) 1 mL/kg/day for 12 weeks
Number of subjects: 186
Study 24815298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 24815298 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove)
Number of subjects: 186
Study 22354361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 309
Study 22354361 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 309
Study 22354361 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraPro Hernia System (UHS)
Number of subjects: 309
Study 22354361 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 309
Study 20192768 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic manipulation in Dictyostelium to study chemotaxis
Number of subjects: 0
Study 18263683 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported depressive symptoms (measured using Geriatric Depression Scale, GDS)
Number of subjects: 257
Study 18263683 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported depressive disorders
Number of subjects: 257
Study 15721727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (CIS) 0.10 mg/kg
Number of subjects: 40
Study 15721727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (ROC) 0.60 mg/kg
Number of subjects: 40
Study 12824971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Number of subjects: 84
Study 12824971 — intervention group
Group type: COMPARATOR
Intervention: 7 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Number of subjects: 84
Study 12824971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin-sulbactam
Number of subjects: 84
Study 12824971 — intervention group
Group type: COMPARATOR
Intervention: 7 days of ampicillin-sulbactam
Number of subjects: 84
Study 10935147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 17255
Study 8858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (TBH) 50 micrograms
Number of subjects: 20
Study 8858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotahaler (RH) 200 micrograms
Number of subjects: 20
Study 8858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler (DH) 200 micrograms
Number of subjects: 20
Study 8858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (TBH)
Number of subjects: 20
Study 1495748 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (9 x 10(6) IU/m2, subcutaneously, twice daily for 3 days before surgery)
Number of subjects: 12
Study 1495748 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 colon cancer patients)
Number of subjects: 12
Study 6088166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.78% sodium monofluorophosphate dentifrice
Number of subjects: 1154
Study 6088166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study 31348005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 60
Study 31348005 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 60
Study 29688200 — intervention group
Group type: EXPERIMENTAL
Intervention: Venarus
Number of subjects: 80
Study 29688200 — intervention group
Group type: COMPARATOR
Intervention: Standard comprehensive conservative treatment
Number of subjects: 80
Study 25652871 — intervention group
Group type: EXPERIMENTAL
Intervention: In-field gait retraining
Number of subjects: 30
Study 25652871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23445797 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 47
Study 23445797 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 47
Study 22149130 — intervention group
Group type: EXPERIMENTAL
Intervention: print‐based feedback
Number of subjects: 239
Study 22149130 — intervention group
Group type: EXPERIMENTAL
Intervention: phone‐based feedback
Number of subjects: 239
Study 22149130 — intervention group
Group type: COMPARATOR
Intervention: contact control
Number of subjects: 239
Study 20731980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (usual care plus a 10-minute videotape/DVD and a printed pamphlet)
Number of subjects: 700
Study 20731980 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (advice not to consume alcohol while pregnant and the opportunity to watch a 30-second television commercial)
Number of subjects: 700
Study 17522901 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery and guided tissue regeneration (GTR)
Number of subjects: 20
Study 17522901 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery alone
Number of subjects: 20
Study 16187469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 300
Study 16187469 — intervention group
Group type: COMPARATOR
Intervention: Oral nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 300
Study 16187469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (diclofenac-paracetamol)
Number of subjects: 300
Study 16187469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-paracetamol combination
Number of subjects: 300
Study 16187469 — intervention group
Group type: EXPERIMENTAL
Intervention: All combinations (NSAIDs, paracetamol, diclofenac-paracetamol)
Number of subjects: 300
Study 16187469 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 300
Study 12519847 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist long protocol (group A; n = 45)
Number of subjects: 142
Study 12519847 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol commencing recombinant FSH on cycle day 2 (group B; n = 48)
Number of subjects: 142
Study 12519847 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol commencing recombinant FSH on cycle day 5 (group C; n = 49)
Number of subjects: 142
Study 11424663 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned medium (CM) by patients T cells
Number of subjects: 15
Study 11424663 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned medium (CM) by T cells of healthy donors
Number of subjects: 15
Study 11424663 — intervention group
Group type: COMPARATOR
Intervention: Normal bone marrow cells
Number of subjects: 15
Study 11424663 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Epo level
Number of subjects: 15
Study 8706778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 9
Study 1353803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray (0.5 mg per shot)
Number of subjects: 227
Study 1353803 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 227
Study 1353803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray
Number of subjects: 227
Study 1353803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray and Placebo nasal spray
Number of subjects: 227
Study 6501724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (34 +/- 22 mg)
Number of subjects: 9
Study 6501724 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (10 +/- 5 mg)
Number of subjects: 9
Study 31182176 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication prescribed on discharge (including neuroleptics, antidepressants, anxiolytics)
Number of subjects: 50
Study 29575951 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training protocol (3 times weekly, 60 minutes per session for 6 months)
Number of subjects: 0
Study 29575951 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 28879617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20
Study 28879617 — intervention group
Group type: COMPARATOR
Intervention: Volume-Matched Moderate-Intensity Continuous Training (CONT)
Number of subjects: 20
Study 26595966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-frequency electrostatic fields (PLIESF)
Number of subjects: 101
Study 26595966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with PLIESF and therapeutic physical exercises
Number of subjects: 101
Study 26595966 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic physical exercises
Number of subjects: 101
Study 24213914 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruptions (STIs) consisting of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy
Number of subjects: 12
Study 24213914 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous treatment
Number of subjects: 12
Study 21144499 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeted at the area of maximal hallucinatory activation calculated from individual fMRI scans during AVH
Number of subjects: 62
Study 21144499 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS directed at the left temporoparietal area (TP)
Number of subjects: 62
Study 21144499 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 62
Study 18065829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation combined with a single bout of resistance exercise (PO + EX)
Number of subjects: 8
Study 18065829 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplementation alone (PO)
Number of subjects: 8
Study 16758243 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg/day; n=20)
Number of subjects: 40
Study 16758243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg/day; n=20)
Number of subjects: 40
Study 12766690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-processing therapy
Number of subjects: 121
Study 12766690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 121
Study 12766690 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment waiting-list condition
Number of subjects: 121
Study 10848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 24
Study 10848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24
Study 10848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 24
Study 10848651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9050084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (8 mg)
Number of subjects: 12
Study 9050084 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10 and 20 mg)
Number of subjects: 12
Study 9050084 — intervention group
Group type: COMPARATOR
Intervention: Pimozide (8 mg) + d-Amphetamine (10 and 20 mg)
Number of subjects: 12
Study 9050084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1315651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (800 mg)
Number of subjects: 27
Study 1315651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6421918 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of sodium cromoglycate (SCG)
Number of subjects: 16
Study 6421918 — intervention group
Group type: COMPARATOR
Intervention: Placebo-lactose (P)
Number of subjects: 16
Study 6421918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment (day 1)
Number of subjects: 16
Study 31441328 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led diabetes prevention workshops (8 sessions, 90 minutes each)
Number of subjects: 402
Study 31441328 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 402
Study 30064685 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple positive platelet microparticles (PMPs) expressing phosphatidylserine and integrin complexes alphaIIb (CD41) and beta3 (CD61)
Number of subjects: 193
Study 27892445 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage (Group A)
Number of subjects: 60
Study 27892445 — intervention group
Group type: COMPARATOR
Intervention: No Drainage (Group B)
Number of subjects: 60